Administration and treatment of activatable anti-CTLA-4 antibodies

Abstract

This invention provides a method for administering and administering an activatable anti-CTLA-4 antibody for the treatment of cancer. [Solution] A method for administering and administering an activatable anti-CTLA-4 antibody, such as activatable ipilimumab, is provided. The method comprises administering the activatable anti-CTLA-4 antibody once every four weeks (Q4W) or once every eight weeks (Q8W).

Claims

1. A method for treating cancer in a human subject requiring such treatment using an activatable anti-CTLA-4 antibody, the method comprising administering the activatable anti-CTLA-4 antibody once every four weeks (Q4W) or once every eight weeks (Q8W); The activatable anti-CTLA-4 antibody here is a. A heavy chain containing the heavy chain variable domain sequence of Sequence ID No. 9; and b. A light chain containing a light chain variable domain sequence selected from the group consisting of sequence numbers 21, 22, and 23. Methods that include...

2. Activatable anti-CTLA-4 antibodies: a. A heavy chain containing the sequence of Sequence ID No. 11; and b. Light chain containing the sequence of Sequence ID No. 24 The method according to claim 1, including the method described in claim 1.

3. The method according to claim 1 or 2, wherein an activatable anti-CTLA-4 antibody is administered at Q8W.

4. The method according to any one of claims 1 to 3, wherein an activatable anti-CTLA-4 antibody is administered in a uniform dose of 240, 800, 1600, or 2400 mg.

5. The method according to claim 4, wherein an activatable anti-CTLA-4 antibody is administered in a uniform dose of 1600 mg Q8W.

6. Cancer, a. Unresectable or metastatic melanoma; and b. Adjunctive therapy for melanoma A method according to any one of claims 1 to 5, selected from the group consisting of the following.

7. A method for treating cancer in human subjects requiring such treatment using an activatable anti-CTLA-4 antibody in combination with nivolumab, comprising administering the activatable anti-CTLA-4 antibody once every four weeks (Q4W) or once every eight weeks (Q8W), wherein the activatable anti-CTLA-4 antibody is: a. A heavy chain containing the heavy chain variable domain sequence of Sequence ID No. 9; and b. A light chain containing a light chain variable domain sequence selected from the group consisting of sequence numbers 21, 22, and 23. Methods that include...

8. Activatable anti-CTLA-4 antibodies: a. A heavy chain containing the sequence of Sequence ID No. 11; and b. Light chain containing the sequence of Sequence ID No. 24 The method according to claim 7, including the method described in claim 7.

9. The method according to claim 7 or claim 8, wherein an activatable anti-CTLA-4 antibody is administered at Q8W.

10. The method according to any one of claims 7-9, wherein an activatable anti-CTLA-4 antibody is administered in a uniform dose of 240, 600, 800, 1200, or 1600 mg.

11. The method according to claim 10, wherein nivolumab is administered in a uniform dose of 480 mg Q4W.

12. The method according to claim 11, wherein activatable ipilimumab is administered in a uniform dose of 600 mg Q4W.

13. The method according to claim 11, wherein activatable ipilimumab is administered in a uniform dose of 1200 mg Q8W.

14. Cancer: a. Advanced renal cell carcinoma; b. Metastatic colorectal cancer with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR); c. Melanoma; d. Non-small cell lung cancer (NSCLC); e. Malignant pleural mesothelioma; and f. hepatocellular carcinoma The method according to any one of claims 7-13, selected from the group consisting of the following.

Images